Joel Ackerman
Known title: DirectorCIK: 0001220630
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Champions Oncology Highlighted in Global PDX Models Shift. Champions Oncology was highlighted in a Yahoo article that discusses the shift toward patient‑derived xenograft (PDX) models in precision oncology. The story compares the company with peers like Charles River, Crown Bioscience, The Jackson Laboratory and Oncodesign, indicating growing industry focus on PDX‑based research. This comparison suggests Champions may benefit from increased demand for its precision oncology solutions. No new financial data were disclosed.
Transaction History
| DVA | ▼ Sell | Open Market | 51,471 | $9.9M | 5/7/2026 | View on chart |
| DVA | ▲ Buy | Grant | 5,706 | $0 | 3/15/2026 | View on chart |
| DVA | ▼ Sell | Tax Withholding | 3,362 | $507K | 3/15/2026 | View on chart |
| DVA | ▼ Sell | Tax Withholding | 33,693 | $5.1M | 3/15/2026 | View on chart |
| DVA | ▼ Sell | Tax Withholding | 5,765 | $869K | 3/15/2026 | View on chart |
| DVA | ▲ Buy | Grant | 6,585 | $0 | 3/10/2026 | View on chart |
| DVA | ▲ Buy | Grant | 65,997 | $0 | 3/10/2026 | View on chart |
| DVA | ▲ Buy | Option Exercise | 44,065 | $4.8M | 2/6/2026 | View on chart |
| DVA | ▼ Sell | Other | 32,168 | $4.8M | 2/6/2026 | View on chart |
| DVA | ▼ Sell | Tax Withholding | 5,100 | $761K | 2/6/2026 | View on chart |
| CSBR | ▲ Buy | Option Exercise | 94,405 | $198K | 10/30/2025 | View on chart |
| DVA | ▲ Buy | Grant | 5,995 | $0 | 3/15/2025 | View on chart |
| DVA | ▼ Sell | Tax Withholding | 3,093 | $444K | 3/15/2025 | View on chart |
| DVA | ▼ Sell | Tax Withholding | 3,331 | $478K | 3/15/2025 | View on chart |
| DVA | ▲ Buy | Grant | 7,221 | $0 | 3/12/2025 | View on chart |
| DVA | ▲ Buy | Grant | 7,394 | $0 | 3/12/2025 | View on chart |
| CSBR | ▲ Buy | Option Exercise | 16,667 | $91K | 10/31/2024 | View on chart |
| CSBR | ▲ Buy | Option Exercise | 88,470 | $186K | 10/31/2024 | View on chart |
| DVA | ▲ Buy | Option Exercise | 78,999 | $6.0M | 9/16/2024 | View on chart |
| DVA | ▼ Sell | Other | 36,684 | $6.0M | 9/16/2024 | View on chart |
| DVA | ▼ Sell | Tax Withholding | 21,602 | $3.5M | 9/16/2024 | View on chart |
| DVA | ▼ Sell | Open Market | 4,740 | $735K | 8/28/2024 | View on chart |
| DVA | ▼ Sell | Open Market | 64,029 | $9.9M | 8/27/2024 | View on chart |
| DVA | ▲ Buy | Grant | 10,977 | $0 | 3/15/2024 | View on chart |
| DVA | ▼ Sell | Tax Withholding | 8,064 | $1.1M | 3/15/2024 | View on chart |
| DVA | ▲ Buy | Grant | 14,349 | $0 | 3/14/2024 | View on chart |
| DVA | ▲ Buy | Grant | 1,445 | $0 | 3/14/2024 | View on chart |
| DVA | ▲ Buy | Option Exercise | 55,000 | $2.9M | 3/6/2024 | View on chart |
| DVA | ▼ Sell | Tax Withholding | 17,149 | $2.3M | 3/6/2024 | View on chart |
| DVA | ▼ Sell | Other | 21,408 | $2.9M | 3/6/2024 | View on chart |
| DVA | ▲ Buy | Option Exercise | 55,000 | $2.9M | 2/21/2024 | View on chart |
| DVA | ▼ Sell | Other | 23,436 | $2.9M | 2/21/2024 | View on chart |
| DVA | ▼ Sell | Tax Withholding | 14,930 | $1.8M | 2/21/2024 | View on chart |
| CSBR | ▲ Buy | Option Exercise | 114,552 | $241K | 10/17/2023 | View on chart |
| DVA | ▼ Sell | Tax Withholding | 7,625 | $739K | 5/15/2023 | View on chart |
| DVA | ▼ Sell | Tax Withholding | 12,861 | $1.2M | 5/15/2023 | View on chart |
| DVA | ▲ Buy | Option Exercise | 56,306 | $3.7M | 5/10/2023 | View on chart |
| DVA | ▼ Sell | Other | 37,059 | $3.7M | 5/10/2023 | View on chart |
| DVA | ▼ Sell | Tax Withholding | 9,826 | $990K | 5/10/2023 | View on chart |
| DVA | ▲ Buy | Grant | 2,790 | $0 | 4/4/2023 | View on chart |
| DVA | ▼ Sell | Tax Withholding | 709 | $54K | 3/15/2023 | View on chart |
| DVA | ▲ Buy | Grant | 23,672 | $0 | 3/15/2023 | View on chart |
| DVA | ▼ Sell | Tax Withholding | 4,260 | $324K | 3/15/2023 | View on chart |
| DVA | ▲ Buy | Grant | 1,387 | $0 | 3/9/2023 | View on chart |
| DVA | ▲ Buy | Grant | 22,400 | $0 | 2/23/2023 | View on chart |
| DVA | ▲ Buy | Grant | 8,343 | $0 | 2/23/2023 | View on chart |
| CSBR | ▲ Buy | Option Exercise | 16,667 | $54K | 10/19/2022 | View on chart |
| DVA | ▼ Sell | Tax Withholding | 9,414 | $942K | 5/15/2022 | View on chart |
| DVA | ▼ Sell | Tax Withholding | 2,875 | $288K | 5/15/2022 | View on chart |
| DVA | ▼ Sell | Tax Withholding | 14,082 | $1.4M | 5/15/2022 | View on chart |
| DVA | ▼ Sell | Tax Withholding | 7,624 | $763K | 5/15/2022 | View on chart |
| DVA | ▲ Buy | Grant | 18,438 | $0 | 4/19/2022 | View on chart |
| DVA | ▲ Buy | Grant | 28,385 | $0 | 4/19/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
DaVita (DVA) Discussed as Potentially Undervalued Cash Producer
Recent articles highlight DaVita as a cash-producing stock that may be undervalued relative to its earnings power. The company has outperformed the broader market recently, with one analysis noting a 58% gain. While the stock is trading near its 52-week low, analysts maintain a higher average price target, suggesting a gap between current price and long-term expectations.
DaVita (DVA) Discussed as Potentially Undervalued Cash Producer. Recent articles highlight DaVita as a cash-producing stock that may be undervalued relative to its earnings power. The company has outperformed the broader market recently, with one analysis noting a 58% gain. While the stock is trading near its 52-week low, analysts maintain a higher average price target, suggesting a gap between current price and long-term expectations.